ライフサイエンスコーパス: MSI

1 MSI analysis of tissue sections exposed to phospholipid

2 MSI of individual cells (of a known cell type) affords a

3 MSI(+) patients were associated with earlier year of dia

4 MSI-H is a good prognostic factor in nonmetastatic colon

5 MSI-H should be a predictive factor because it is associ

6 MSI-H tumors associated with diminished intra-tumoral he

7 MSI-H/MMR-D is predictive of LS across a much broader tu

8 MSI-H/MMR-D tumors, for which pembrolizumab is a standar

9 MSI-high status was assigned based on analysis of 114 in

10 MSI/IHC and PREMM(5) effectively identify patients with

11 MSI/IHC and PREMM(5) had comparable sensitivity for iden

12 igh-resolution (fwhm, at m/z 410 of 160 000) MSI data.

13 ated with tumor differentiation (p = 0.045), MSI status (p = 0.021) and BRAF mutation (p = 0.001).

14 plete marker data were classified as type 1 (MSI-high, CIMP-positive, with pathogenic mutations in BR

15 The use of negative ion mode MALDI-2-MSI could constitute a valuable tool in glycobiology res

16 d with laser-induced postionization (MALDI-2-MSI) to simultaneously visualize the distribution of sev

17 were observed than that indicated by the 2D-MSI data, suggesting that quantitative analysis of molec

18 Genetic sequences from 320 MSI tumor biopsies and matched healthy tissues in The Ca

19 A 3D MSI dataset demonstrated that these molecules were obser

20 c neighbor embedding to nonlinearly align 3D MSI to MRI data, identify and reconstruct biologically r

21 Automatic coregistration between 3D MSI/MRI is a computationally challenging process due to

22 l single-plaque analysis in reconstructed 3D-MSI objects revealed the Abeta(1-42Arc) peptide to be lo

23 Primary comparison groups were between 4450 MSI-negative(-) and 636 MSI-positive(+) patients.

24 genic mutations in BRAF or KRAS), or type 5 (MSI-high, no CIMP, no pathogenic mutations in BRAF or KR

25 ps were between 4450 MSI-negative(-) and 636 MSI-positive(+) patients.

26 ution analysis of single region-data from 64 MSI GOAs show that chromosome 8 gains are early genetic

27 ) and equal 97.5% (468/484) specificity; 64% MSI-H and 73% MMR deficient tumours unexplained by LS or

28 dence for either, making this LPS-to-Lipid A-MSI (LLA-MSI) method, compatible with simultaneous host-

29 enetrance PVs, and any PVs) who had abnormal MSI/IHC testing and/or PREMM(5) score >= 2.5%.

30 t arrays (NAPA), are emerging as alternative MSI techniques that can provide complementary insight in

31 atients (96.6% v 96.6%; P = 1.000), although MSI/IHC had significantly superior specificity for LS (8

32 atients with CRC and/or EC with LS, although MSI/IHC has better specificity for LS.

33 In women, the relation between BMI and MSI-high CRC seems to be stronger than that between BMI

34 cells isolated from both healthy donors and MSI-H cancer patients.

35 mor programmed death-ligand 1 expression and MSI-H/MMR-D status were not associated with objective re

36 Furthermore, tau and MSI interactions induced impairment of nuclear/cytoplasm

37 is thereby readily applicable to almost any MSI data set.

38 We assessed MSI status and PD-1 & PD-L1 expression.

39 itate broader use of liquid-extraction-based MSI in biological research, drug discovery, and clinical

40 Both groups demonstrated normal behavioural MSI.

41 NCDB) to investigate the association between MSI and pathologic complete response (pCR) in this patie

42 driven by the aberrant interactions between MSI and tau in the nuclei associated with age-dependent

43 r the comparison of technical and biological MSI replicates.

44 15%, n = 55) when measuring urinary HP-G by MSI-CE-MS/MS as compared to total hydrolyzed urinary HP

45 n chemical detail at the whole-worm level by MSI.

46 evaluation of amyloid plaque-like objects by MSI: a fast PLAQUE PICKER tool that enables a statistica

47 ization of the massive data sets produced by MSI.

48 e innate diversity within molecular classes, MSI platforms capable of detecting a wide array of speci

49 The aim of this study was to compare MSI/IHC and the PREMM(5) prediction model to identify ca

50 nging process due to dimensional complexity, MSI data sparsity, lack of direct spatial-correspondence

51 Comprehensive MSI lipid mapping requires measurements in both ion pola

52 stability and/or mismatch repair-deficiency (MSI/IHC) and clinical prediction models effectively scre

53 llite-high and/or mismatch repair deficient (MSI-H/MMR-D) status, and somatic and germline genomic co

54 scue the viability phenotype of WRN-depleted MSI-H cancer cells.

55 A combination of nano-DESI MSI and LC-MS/MS lipidomics is particularly useful for e

56 performance to the capillary-based nano-DESI MSI in terms of stability and sensitivity; a spatial res

57 vide a detailed description of the nano-DESI MSI platform, fabrication of the nano-DESI and shear for

58 ated microfluidic probe (iMFP) for nano-DESI MSI.

59 in desorption electrospray ionization (DESI) MSI, which enables cell-type-specific and in situ metabo

60 Desorption electrospray ionization (DESI)-MSI defined regions of a hypoxic core and a proliferativ

61 We accomplish this by combining DESI-MSI with immunofluorescence staining using specific cell

62 y ionization-mass spectrometry imaging (DESI-MSI) facilitates the convergence of analytical chemistry

63 desorption electrospray ionization-MSI (DESI-MSI) and bespoke chemometrics to assess the phospholipid

64 he relatively low spatial resolution of DESI-MSI and provides a new platform for in situ metabolic in

65 In summary, DESI-MSI identified distinct lipid composition between DCIS a

66 Thus, DESI-MSI can objectively identify invasive esophageal adenoca

67 for accelerated diagnosis studies using DESI-MSI in the upper gastrointestinal endoscopy suite, as we

68 olecular subtypes of breast cancer with DESI-MSI.

69 Deep learning can detect MSI and dMMR in tumor samples on routine histology slide

70 pecific mutations based on age of diagnosis, MSI status, and colon versus rectum subsite.

71 number of mass spectra associated with each MSI sample can represent a challenge for designing model

72 tomated fashion, employing rigid and elastic MSI image registration using structured and plaque-unrel

73 vidual internal calibration curves for every MSI pixel.

74 8.6%, including 8.9% for MSI(-) and 5.9% for MSI(+) tumors (P = 0.01).

75 verall pCR rate was 8.6%, including 8.9% for MSI(-) and 5.9% for MSI(+) tumors (P = 0.01).

76 des and findings from molecular analyses for MSI and dMMR from 8836 colorectal tumors (of all stages)

77 ical samples is particularly challenging for MSI approaches, as options to appropriately address mole

78 geneity in GBM biology and opportunities for MSI investigations.See related article by Randall et al.

79 vulnerability and promising drug target for MSI cancers.

80 y advanced rectal cancer who were tested for MSI and treated definitively with chemoradiation followe

81 and/or MMR-D tumors now supports testing for MSI in all advanced solid tumors.

82 nity to develop a novel targeted therapy for MSI-H cancers.

83 nt of therapeutic agents that target WRN for MSI-associated cancers.

84 t success of immunotherapy in high-frequency MSI (MSI-H) and/or MMR-D tumors now supports testing for

85 Functional MSI thus represents a new and generalisable method for i

86 eduction of the visual P100 latency, greater MSI-related slowing of the auditory P200 and an overall

87 0.3% (37 of 14,020) of patients with MSI-H, MSI-indeterminate, and microsatellite-stable tumors, res

88 tigens shared across sporadic and hereditary MSI tumors.

89 rability of microsatellite instability-high (MSI-H) cancer cells.

90 Microsatellite instability-high (MSI-H) tumors are characterized by high tumor mutation b

91 ycolysis in microsatellite instability-high (MSI-H) tumors, suggesting glycolysis as a potential targ

92 We hypothesize that MSI-High (MSI-H) patients have favorable survival due to increased

93 However, MSI is not effective for imaging FFPE tissues because of

94 However, MSI-H is not a predictive factor because it is not relat

95 ablation inductively coupled plasma (LA-ICP)-MSI analysis localized endogenous elements including mag

96 Interestingly, LA-ICP-MSI experiments reveal that the NPSCs primarily localize

97 from MALDI-MSI and iron signals from LA-ICP-MSI to overlay the images.

98 led plasma mass spectrometry imaging (LA-ICP-MSI) can be used together to obtain nanomaterial distrib

99 dynamic range combined in a 21T MALDI FT-ICR MSI experiment enable researchers to visualize molecular

100 for ambient mass-spectrometry-based imaging (MSI) methods.

101 By use of MALDI-MS imaging (MSI) in combination with PNGase F treatment, also spatia

102 , Raman spectroscopy, multispectral imaging (MSI), and macro X-ray fluorescence (MA-XRF) with minimal

103 s quantified with mass spectrometry imaging (MSI) can support objective diagnosis in minutes using a

104 Mass spectrometry imaging (MSI) characterizes the molecular composition of tissues

105 visualization of mass spectrometry imaging (MSI) data.

106 MALDI mass spectrometry imaging (MSI) enables label-free, spatially resolved analysis of

107 Mass spectrometry imaging (MSI) enables the visualization of the spatiotemporal dis

108 rix for MALDI-TOF mass spectrometry imaging (MSI) for studying the mouse brain.

109 Mass spectrometry imaging (MSI) has become an important tool for 2D profiling of bi

110 Mass spectrometry imaging (MSI) has the potential to reveal the localization of tho

111 Mass spectrometry imaging (MSI) is a promising technique to assess the spatial dist

112 Mass spectrometry imaging (MSI) is a technique that provides comprehensive molecula

113 Mass spectrometry imaging (MSI) is an established analytical tool capable of defini

114 e present a novel mass spectrometry imaging (MSI) method for assaying the spatial distribution of enz

115 ily revealed with mass spectrometry imaging (MSI) methods, and the resulting lipid distributions serv

116 additive value of mass spectrometry imaging (MSI) of atherosclerosis-affine Gadofluorine P for molecu

117 is widely used in mass spectrometry imaging (MSI) of molecules in biological samples.

118 onization (MALDI) mass spectrometry imaging (MSI) provides a unique in situ chemical profile that can

119 onization (MALDI) mass spectrometry imaging (MSI) requires instrumentation that is capable of high ma

120 A mass spectrometry imaging (MSI) study by Randall and colleagues in this issue provi

121 terest across all mass spectrometry imaging (MSI) technologies.

122 e (FT-ICR), MALDI mass spectrometry imaging (MSI) to image the distribution of endogenous metabolites

123 his work, we used mass spectrometry imaging (MSI) to map metabolites and lipids in patient-derived xe

124 In quantitative mass spectrometry imaging (MSI), the gold standard adds a single structural homolog

125 rption/ionization mass spectrometry imaging (MSI), we were for the first time able to demonstrate, in

126 ue in the case of mass spectrometry imaging (MSI), where the use of different ionization sources allo

127 onization (LAESI) mass spectrometry imaging (MSI).

128 to bind to the most frequent MHC alleles in MSI-H patient cohorts.

129 duces widespread DNA double-strand breaks in MSI cells, leading to cell cycle arrest and/or apoptosis

130 toward accurate subtissue classification in MSI, enabling rapid distinction between tissue types and

131 Kinase fusions in MSI-H colorectal carcinoma were associated with sporadic

132 derived from shared frameshift mutations in MSI-H cancer and Lynch syndrome patients, suitable for t

133 optosis and cell cycle arrest selectively in MSI models.

134 -dinucleotide repeats are highly unstable in MSI cells and undergo large-scale expansions, distinct f

135 ervised classification, which takes as input MSI spectra, and assigns class labels to subtissue locat

136 Microsatellite instability (MSI) and mismatch-repair deficiency (dMMR) in colorectal

137 tionship between microsatellite instability (MSI) and response to neoadjuvant chemoradiation in recta

138 at the degree of microsatellite instability (MSI) and resultant mutational load, in part, underlies t

139 Tumors with microsatellite instability (MSI) are caused by a defective DNA mismatch repair syste

140 in patients with microsatellite instability (MSI) cancers, but no such correlations were found for th

141 r cell-intrinsic microsatellite instability (MSI) signature, which was efficiently exported to gastri

142 nformation about microsatellite instability (MSI) status and pathology assessment.

143 ancer cells with microsatellite instability (MSI), a form of genetic hypermutability that arises from

144 chemistry (IHC), microsatellite instability (MSI), and targeted MLH1-methylation testing.

145 factors such as microsatellite instability (MSI), cancer subsite within the colon versus rectum, and

146 d information on microsatellite instability (MSI), CpG island methylator phenotype (CIMP), and mutati

147 lar subtypes for microsatellite instability (MSI), CpG island methylator phenotype (CIMP), and somati

148 ogical features: microsatellite instability (MSI), CpG island methylator phenotype (CIMP), B-Raf prot

149 nts, focusing on microsatellite instability (MSI), genetic mutations, CpG island methylator phenotype

150 types, including microsatellite instability (MSI), homologous recombination deficiency (HRD) enriched

151 al burden (TMB), microsatellite instability (MSI), programmed cell death protein 1 (PD-1), and its li

152 in patients with microsatellite instability (MSI)-high tumors (n = 11) and 36.2% (26.5% to 46.7%) in

153 An analysis of microsatellite instable (MSI) cell lines reveals the dysregulation of specific pr

154 or the Sentinel-2 Multi-Spectral Instrument (MSI).

155 utatively underlie Multisensory Integration (MSI) deficits in Autism Spectrum Disorder (ASD).

156 changing numbers of metal-support interface (MSI) sites as water coverage changes with temperature.

157 he identification of a cancer cell-intrinsic MSI signature, recognizing a subset of MSS patients with

158 , we used desorption electrospray ionization-MSI (DESI-MSI) and bespoke chemometrics to assess the ph

159 erational parameters, both LAAPPI- and LAESI-MSI with a spatial resolution of 70 mum produced high-qu

160 tra hinders the productive analysis of large MSI datasets when utilizing standard tools.

161 Our results demonstrate that NAPA-LDI-MSI is capable of imaging and potentially differentiatin

162 ionization mass spectrometry imaging (UV-LDI-MSI) using monoisotopic silver-109 nanoparticle-enhanced

163 ysiological level, the ASD group showed less MSI-related reduction of the visual P100 latency, greate

164 either, making this LPS-to-Lipid A-MSI (LLA-MSI) method, compatible with simultaneous host-pathogen

165 issues, which inspires a broad use of LD-LTP MSI in plant chemistry studies.

166 antigen epitope preservation to allow MALDI MSI to be performed and directly followed by IHC analysi

167 method for simple postionization in AP-MALDI MSI.

168 highest mass spectral performance for MALDI MSI experiments, and often reveals molecular features th

169 ontaining metabolites with CHC-Mal for MALDI MSI was also possible when using aged tissue in the pres

170 lfhydryl groups in tissue is known for MALDI MSI.

171 Here, MALDI MSI at 21T is demonstrated for the first time: mass reso

172 /ionization mass spectrometry imaging (MALDI MSI) and laser scanning confocal microscopy (LSCM).

173 /ionization mass spectrometry imaging (MALDI MSI) is a powerful technique for spatially resolved meta

174 /ionization mass spectrometry imaging (MALDI MSI) is an established tool for the investigation of for

175 ionization mass spectrometry imaging (MALDI MSI) technologies offers a high promise to deeper unders

176 /ionization mass spectrometry imaging (MALDI MSI)-based study was designed in order to selectively ma

177 begins within the normal time scale of MALDI MSI sample preparation.

178 The MALDI MSI protocol was optimized in terms of fiducial composit

179 lective detection of free thiols using MALDI MSI.

180 MALDI-MSI experiments on spleen tissues from intravenously inj

181 lipid coverages between the NAPA- and MALDI-MSI platforms presents the possibility of selective lipi

182 r, robust and accurate quantitation by MALDI-MSI still remains a challenge.

183 a substantial step toward establishing MALDI-MSI as a fully quantitative validated method.

184 -tissue derivatization was applied for MALDI-MSI of N-glycans from human laryngeal cancer and ovarian

185 omplish by using the heme signals from MALDI-MSI and iron signals from LA-ICP-MSI to overlay the imag

186 ernal control for peptide and N-glycan MALDI-MSI throughout the experiment.

187 /ionization mass spectrometry imaging (MALDI-MSI) and laser ablation inductively coupled plasma mass

188 /ionization mass spectrometry imaging (MALDI-MSI) has been widely applied to the discovery of potenti

189 /ionization mass spectrometry imaging (MALDI-MSI) is an established tool in drug development, which e

190 ionization mass spectrometry imaging (MALDI-MSI) is widely used to visualize and analyze the distrib

191 /ionization mass spectrometry imaging (MALDI-MSI) was developed for analysis of N-glycans from FFPE t

192 /ionization-mass spectrometry imaging (MALDI-MSI) within pharmaceutical research.

193 /ionization mass spectrometry imaging (MALDI-MSI).

194 abilities of BzPy as a multifunctional MALDI-MSI matrix are demonstrated by imaging endogenous and PB

195 ded by NAPA-MSI is compared to that of MALDI-MSI using two common MALDI matrices.

196 n-mass spectrometry imaging with PBCs (MALDI-MSI-PBC) as a drug screening platform.

197 We present a quantitative MALDI-MSI method using two instruments with different types of

198 d allows dual-polarity high-resolution MALDI-MSI and MALDI MS(2)I studies.

199 y, five micron high-spatial resolution MALDI-MSI revealed that Arabidopsides are localized to the chl

200 Second, MALDI-MSI of kidney tissues was performed to study the spatial

201 y spectra are acquired during a single MALDI-MSI experiment or data from independent experiments are

202 erent GPL classes observed in standard MALDI-MSI.

203 between different classes of GPL under MALDI-MSI conditions.

204 gs, indicating that coupling PBCs with MALDI-MSI has the potential to develop rapid, large-scale, and

205 fic GPL classes and analyzed them with MALDI-MSI in positive- and negative-ion modes.

206 -tissue labeling strategy coupled with MALDI-MSI shows great potential to spatially characterize N-gl

207 nts in both instrumentation and methodology, MSI of tissue samples at single-cell resolution remains

208 MOLI MSI was applied to the imaging of normal mouse brain rev

209 use brain tissue sections and imaged by MOLI MSI.

210 We describe MOLI MSI for the first time and highlight its potential for s

211 To assess the potential of MOLI MSI to detect pathogens directly from tissue, a pseudoin

212 Similarly, MOLI MSI showed distinct fatty acyl composition in tumor regi

213 (DB) positions are not identifiable in most MSI experiments.

214 cability of the novel ambient LARESI SRM/MRM MSI method to both investigating and discovering cancer

215 cess of immunotherapy in high-frequency MSI (MSI-H) and/or MMR-D tumors now supports testing for MSI

216 Here, multimodal MSI techniques were employed to characterize a novel agg

217 and the RNA-binding proteins (RBPs) Musashi (MSI) are reported in Alzheimer's disease (AD).

218 d chemotherapy regardless of the mutational, MSI, and CMS profiles.

219 erage of mouse brain lipids afforded by NAPA-MSI is compared to that of MALDI-MSI using two common MA

220 tional processes, (d) thus leading to normal MSI at the behavioural level.

221 Among patients with normal MSI/IHC, PREMM(5) identified 84.2% and 83.3% of high-ris

222 ) score >= 2.5%, including those with normal MSI/IHC, should be offered multigene panel testing.

223 mutations in BRAF but not KRAS), type 2 (not MSI-high, CIMP-positive, with pathogenic mutations in BR

224 mutations in BRAF but not KRAS), type 3 (not MSI-high or CIMP, with pathogenic mutations in KRAS but

225 mutations in KRAS but not BRAF), type 4 (not MSI-high or CIMP, no pathogenic mutations in BRAF or KRA

226 tic insight for pathological accumulation of MSI/tau aggregates providing a potential basis for thera

227 algorithm and a workflow for the analyses of MSI experiments, that detects components of single-ion i

228 l custom distance metric for the analysis of MSI data.

229 Quantitative analysis of MSI datasets is typically performed on single pixels or

230 at our workflow facilitates incorporation of MSI in neuroscience-related topics, including the study

231 s, we argue that electro-cortical indices of MSI deficits in ASD: (a) can be detected in early-adoles

232 y delayed and spatially constrained onset of MSI.

233 tential target to overcome the resistance of MSI-H tumors to immune checkpoint blockade.

234 a prerequisite for combining the results of MSI and other single-cell modalities (e.g. mass cytometr

235 ly and more strongly associated with risk of MSI CRC (OR per 5 kg/m2: 1.69; 95% CI: 1.34, 2.12; Phete

236 However, the role of MSI and tau interaction in their aggregation process and

237 GMMs to account for the spatial structure of MSI.

238 ellite stable (MSS) patients, of a subset of MSI-like tumors with common molecular aspects and signif

239 eoantigen-based vaccine for the treatment of MSI tumors.

240 ivation selectively impairs the viability of MSI-H but not microsatellite stable (MSS) colorectal and

241 can be used for exploratory visualization of MSI datasets without prior deep chemical or histological

242 cts colorectal cancer specimens with dMMR or MSI using H&E-stained slides; it detected tissues with d

243 g detector identified specimens with dMMR or MSI with a mean AUROC curve of 0.92 (lower bound, 0.91;

244 IHC outperformed MSI for tumour triage and reliably identified both germl

245 from intact (smooth) LPS from host-pathogen MSI studies, proved elusive.

246 onality reduction of large (>100 000 pixels) MSI data sets.

247 ng laser ablation inductively coupled plasma MSI on adjacent serial tissue sections.

248 nced response to anti-PD-1 treatment in pMMR-MSI-L CRC and melanoma.

249 ient or microsatellite instability-low (pMMR-MSI-L) tumors have low mutation burden and constitute ~8

250 r METTL14 and STAT1 in 59 patients with pMMR-MSI-L CRC tumors.

251 chieve clinical benefit to treat and prevent MSI tumors.

252 However, the mechanism by which WRN protects MSI-associated cancers from double-strand breaks remains

253 atrix-assisted laser desorption/ionization-Q-MSI (MALDI-Q-MSI), using a mixture of three isotopically

254 g a high agreement between LC-MS and MALDI-Q-MSI (Pearson correlation r = 0.87).

255 d laser desorption/ionization-Q-MSI (MALDI-Q-MSI), using a mixture of three isotopically labeled vers

256 ased culturing workflow that enables a rapid MSI-compatible steam inactivation of pathogens and gener

257 We report robust MSI effects at behavioural and electrophysiological leve

258 sent study set out to investigate non-social MSI stimuli and their electrophysiological correlates in

259 capillary electrophoresis-mass spectrometry (MSI-CE-MS) and CE with indirect UV detection are used, r

260 ry electrophoresis-tandem mass spectrometry (MSI-CE-MS/MS).

261 er risk for cases with microsatellite stable/MSI-low, CIMP-negative, BRAF-wildtype, and KRAS-wildtype

262 favorable prognostic marker for early stage MSI colorectal cancer.

263 Along with lower T stage, MSI(+) cases were significantly associated with a reduce

264 e-dependent extracellular depositions of tau/MSI complexes.

265 testing was more discriminatory for LS than MSI with targeted methylation testing, with 100% versus

266 For the first time, we demonstrate that MSI-NACE-MS offers a rapid yet robust platform for direc

267 We hypothesize that MSI-High (MSI-H) patients have favorable survival due to

268 dy was to improve sample preparation so that MSI could provide comprehensive and reproducible neurope

269 isualization of hyperspectral images and the MSI data specifically, such as principal component analy

270 heterolytic H(2) activation directly at the MSI (E(app) ~ 25 kJ/mol) and significantly slower hetero

271 This approach enabled the MSI-assisted localization of pancreatic peptides express

272 evant molecular patterns in 3D, and fuse the MSI datacube to the MRI space.

273 turing valuable information contained in the MSI data.

274 ohorts, PREMM(5) had superior sensitivity to MSI/IHC at identifying patients with any high-penetrance

275 seems to be the first application of UMAP to MSI data, we assess the value of applying alternative di

276 Moreover, MALDI-TOF MSI results were obtained for lipid distributions, makin

277 s misalignment in axial time-of-flight (TOF) MSI continues to be a serious issue.

278 iously treated patients, regardless of tumor MSI status, the median DOR was 21.2 months (95% CI, 7.6

279 prior systemic therapy, regardless of tumor MSI status.

280 Also, total hydrolyzed plasma FAs using MSI-NACE-MS was compared to mean concentrations reported

281 assification of whole tissue specimens using MSI data, which naturally preserves the spatial informat

282 (12/21) of colorectal carcinoma fusions were MSI-H/MMR-D.

283 c repositories in many research fields where MSI is commonly applied; yet, there is no standardized p

284 However, whether MSI can objectively identify primary esophageal adenocar

285 pression of DNA repair genes associated with MSI-H.

286 For the association of BMI with MSI CRC, we observed effect modification by sex (Pintera

287 ive associations were stronger compared with MSI-high, CIMP-positive, BRAF-mutated, or KRAS-mutated t

288 iobanks can effectively be investigated with MSI.

289 Among patients with LS with MSI-H/I tumors, 50% (33 of 66) had tumors other than CRC

290 mor biopsies of 20 independent patients with MSI colorectal cancer revealed that a median number of 3

291 e, recognizing a subset of MSS patients with MSI transcriptional traits, endowed with better prognosi

292 m indel mutations shared among patients with MSI-H endometrial, colorectal, and stomach cancers.

293 9), and 0.3% (37 of 14,020) of patients with MSI-H, MSI-indeterminate, and microsatellite-stable tumo

294 Two of six patients with MSI-H/MMR-D tumors responded.

295 rter time of DSS compared with patients with MSI-high tumors (HR(DSS) 0.42; 95% CI 0.27-0.64), regard

296 ific neoantigens shared across patients with MSI.

297 We confirm the association of rs1800734 with MSI+ but not MSS cancer risk in our own data and by meta

298 p-learning detector to identify samples with MSI from these slides; performance was assessed by cross

299 Specimens with MSI were identified by genetic analyses.

300 Patients without MSI-high tumors had significantly shorter time of DSS co